[Apha Biz=(Chicago) Reporter Paul Lee] Lee Han-seung, vice president of GobioLab, attended 'KIW 2023' on the 13th. "On the other hand, Gobiolab will be developed for oral use."

GLP-1 is a hormone that is secreted in our bodies when we eat food. It sends a signal to the brain to reduce hunger. It is an injection that is administered once a week.

GobioLab's new drug candidate for obesity treatment, KBLP-004, administers three strains with anti-obesity effects for oral use.

It plans to lower costs compared to the existing injection type GLP-1 obesity treatment.

GobioLab has also secured cash generation capabilities through its health functional food business. In March last year, we established 'WeBiom', a joint venture between GobioLab and E-Mart. It achieved sales of 10 billion won within 10 months of its establishment. It has already made sales of 14 billion won in the first half of this year. It is expected to record annual sales of 30 billion won this year.

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]